Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study).

"Conflict of Interest R.F.S. reports research grants from AstraZeneca, PlaqueTec; Honoraria from AstraZeneca; Consultant/Advisory Board fees from AstraZeneca, Actelion, Avacta, Bayer, Bristol Myers Squibb/Pfizer, Idorsia, Novartis and The Medicines Company. Other authors have no disclosures."

"Funding This study was funded through a British Heart Foundation clinical research training fellowship for Dr Wael Sumaya (FS/15/82/31824). "

" This was a single-centre, single-arm, open-label pharmacodynamic study. All study patients provided informed verbal consent pre-PPCI followed by written consent as soon as possible following PPCI according to a protocol approved by the local research ethics committee and the Medicines and Healthcare Products Regulatory Agency, UK. The trial was registered at http://clinicaltrials.gov (unique identifier: NCT03146858). "